Last mentioned: Mar 24, 2026
2025 Annual Results
Fosun Pharma officially releases its full-year financial performance for 2025.
US FDA Approval
Key biosimilar assets receive final marketing authorization for the US market.
CAR-T Expansion
Yescarta receives expanded indication approval for second-line treatment in China.
ADC Platform Milestone
First internally developed ADC candidate enters Phase II clinical trials.
Fosun Pharma (2196.HK) reported its 2025 annual results, highlighting a significant shift toward innovative drug revenue and successful international commercialization of its biosimilar portfolio. The company's strategic focus on oncology and high-value therapeutics continues to drive growth despite a challenging global macroeconomic environment.
This page surfaces every story mentioning Kite Pharma across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Kite Pharma was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |